The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer

Valentine B. Andela, Michael Pirri, Edward M. Schwarz, Edward J. Puzas, Regis J. O'Keefe, Joseph D Rosenblatt, Randy N. Rosier

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Farnesyl transferase inhibitors have emerged as bona fide anticancer agents whereas the development of geranylgeranyl transferase inhibitors has been mitigated by overt systemic toxicities. Evidence suggests that the therapeutic value of farnesyl transferase inhibitors is an indirect result of perturbations in the function of geranylgeranylated Rho proteins. To address this question, we used inhibitors of the mevalonate synthesis pathway to decrease cellular levels of farnesyl and geranylgeranyl isoprenoids and supplemented our culture systems with exogenous isoprenoids accordingly. Using a murine lung alveolar carcinoma cell line (Line 1), we report a dose-dependent inhibition of tumor cell proliferation, adhesion and invasiveness, in response to alendronate (3-30 μmol/L) and mevastatin (1-10 μmol/L). Supplementation of cultures with geranylgeranyl pyrophosphates (100 μmol/L) was observed to rescue drug-induced phenotypic changes whereas farnesyl pyrophosphate (100 μmol/L) had a minimal effect. Our observations highlight the mevalonate synthesis pathway as a target for anticancer therapies and suggest a greater role for geranylgeranylated proteins in cellular processes germane to cancer.

Original languageEnglish
JournalClinical Orthopaedics and Related Research
Issue number415 SUPPL.
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Mevalonic Acid
Transferases
Terpenes
Drug Repositioning
Bronchiolo-Alveolar Adenocarcinoma
Alendronate
Neoplasms
Cell Adhesion
Antineoplastic Agents
Proteins
Therapeutics
Cell Proliferation
Cell Line
Lung

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Andela, V. B., Pirri, M., Schwarz, E. M., Puzas, E. J., O'Keefe, R. J., Rosenblatt, J. D., & Rosier, R. N. (2003). The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer. Clinical Orthopaedics and Related Research, (415 SUPPL.).

The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer. / Andela, Valentine B.; Pirri, Michael; Schwarz, Edward M.; Puzas, Edward J.; O'Keefe, Regis J.; Rosenblatt, Joseph D; Rosier, Randy N.

In: Clinical Orthopaedics and Related Research, No. 415 SUPPL., 01.10.2003.

Research output: Contribution to journalArticle

Andela, VB, Pirri, M, Schwarz, EM, Puzas, EJ, O'Keefe, RJ, Rosenblatt, JD & Rosier, RN 2003, 'The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer', Clinical Orthopaedics and Related Research, no. 415 SUPPL..
Andela VB, Pirri M, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosenblatt JD et al. The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer. Clinical Orthopaedics and Related Research. 2003 Oct 1;(415 SUPPL.).
Andela, Valentine B. ; Pirri, Michael ; Schwarz, Edward M. ; Puzas, Edward J. ; O'Keefe, Regis J. ; Rosenblatt, Joseph D ; Rosier, Randy N. / The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer. In: Clinical Orthopaedics and Related Research. 2003 ; No. 415 SUPPL.
@article{d3ef567bfbf84a44b57c4b26c9d25973,
title = "The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer",
abstract = "Farnesyl transferase inhibitors have emerged as bona fide anticancer agents whereas the development of geranylgeranyl transferase inhibitors has been mitigated by overt systemic toxicities. Evidence suggests that the therapeutic value of farnesyl transferase inhibitors is an indirect result of perturbations in the function of geranylgeranylated Rho proteins. To address this question, we used inhibitors of the mevalonate synthesis pathway to decrease cellular levels of farnesyl and geranylgeranyl isoprenoids and supplemented our culture systems with exogenous isoprenoids accordingly. Using a murine lung alveolar carcinoma cell line (Line 1), we report a dose-dependent inhibition of tumor cell proliferation, adhesion and invasiveness, in response to alendronate (3-30 μmol/L) and mevastatin (1-10 μmol/L). Supplementation of cultures with geranylgeranyl pyrophosphates (100 μmol/L) was observed to rescue drug-induced phenotypic changes whereas farnesyl pyrophosphate (100 μmol/L) had a minimal effect. Our observations highlight the mevalonate synthesis pathway as a target for anticancer therapies and suggest a greater role for geranylgeranylated proteins in cellular processes germane to cancer.",
author = "Andela, {Valentine B.} and Michael Pirri and Schwarz, {Edward M.} and Puzas, {Edward J.} and O'Keefe, {Regis J.} and Rosenblatt, {Joseph D} and Rosier, {Randy N.}",
year = "2003",
month = "10",
day = "1",
language = "English",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "415 SUPPL.",

}

TY - JOUR

T1 - The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer

AU - Andela, Valentine B.

AU - Pirri, Michael

AU - Schwarz, Edward M.

AU - Puzas, Edward J.

AU - O'Keefe, Regis J.

AU - Rosenblatt, Joseph D

AU - Rosier, Randy N.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Farnesyl transferase inhibitors have emerged as bona fide anticancer agents whereas the development of geranylgeranyl transferase inhibitors has been mitigated by overt systemic toxicities. Evidence suggests that the therapeutic value of farnesyl transferase inhibitors is an indirect result of perturbations in the function of geranylgeranylated Rho proteins. To address this question, we used inhibitors of the mevalonate synthesis pathway to decrease cellular levels of farnesyl and geranylgeranyl isoprenoids and supplemented our culture systems with exogenous isoprenoids accordingly. Using a murine lung alveolar carcinoma cell line (Line 1), we report a dose-dependent inhibition of tumor cell proliferation, adhesion and invasiveness, in response to alendronate (3-30 μmol/L) and mevastatin (1-10 μmol/L). Supplementation of cultures with geranylgeranyl pyrophosphates (100 μmol/L) was observed to rescue drug-induced phenotypic changes whereas farnesyl pyrophosphate (100 μmol/L) had a minimal effect. Our observations highlight the mevalonate synthesis pathway as a target for anticancer therapies and suggest a greater role for geranylgeranylated proteins in cellular processes germane to cancer.

AB - Farnesyl transferase inhibitors have emerged as bona fide anticancer agents whereas the development of geranylgeranyl transferase inhibitors has been mitigated by overt systemic toxicities. Evidence suggests that the therapeutic value of farnesyl transferase inhibitors is an indirect result of perturbations in the function of geranylgeranylated Rho proteins. To address this question, we used inhibitors of the mevalonate synthesis pathway to decrease cellular levels of farnesyl and geranylgeranyl isoprenoids and supplemented our culture systems with exogenous isoprenoids accordingly. Using a murine lung alveolar carcinoma cell line (Line 1), we report a dose-dependent inhibition of tumor cell proliferation, adhesion and invasiveness, in response to alendronate (3-30 μmol/L) and mevastatin (1-10 μmol/L). Supplementation of cultures with geranylgeranyl pyrophosphates (100 μmol/L) was observed to rescue drug-induced phenotypic changes whereas farnesyl pyrophosphate (100 μmol/L) had a minimal effect. Our observations highlight the mevalonate synthesis pathway as a target for anticancer therapies and suggest a greater role for geranylgeranylated proteins in cellular processes germane to cancer.

UR - http://www.scopus.com/inward/record.url?scp=0142219301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142219301&partnerID=8YFLogxK

M3 - Article

C2 - 14600593

AN - SCOPUS:0142219301

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 415 SUPPL.

ER -